Do hormones influence melanoma? Facts and controversies

Clinics in Dermatology

Volumn 28, Issue 3, 2010, Pages 287-292

  Gupta, Amie ^a   Driscoll, Marcia S ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; ORAL CONTRACEPTIVE AGENT;

ARTICLE; CANCER RISK; CLINICAL TRIAL; DRUG EFFECT; DRUG USE; HORMONE ACTION; HORMONE SUBSTITUTION; HUMAN; MELANOMA; PATIENT COUNSELING; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; CHEMICALLY INDUCED; DIRECTIVE COUNSELING; FEMALE; NEOPLASMS, HORMONE-DEPENDENT; PHYSIOLOGY; PREGNANCY COMPLICATIONS, NEOPLASTIC; SKIN NEOPLASMS;

CONTRACEPTIVES, ORAL; DIRECTIVE COUNSELING; FEMALE; HORMONE REPLACEMENT THERAPY; HORMONES; HUMANS; MELANOMA; NEOPLASMS, HORMONE-DEPENDENT; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; RISK FACTORS; SKIN NEOPLASMS;

EID: 77953555128     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2010.04.003     Document Type: Article

References (58)

1. Strouse J.J., Fears T.R., Tucker M.A., et al. Pediatric melanoma: risk factor and survival analysis of the surveillance, epidemiology, and end results database. J Clin Oncol 2005, 23:4735-4741.
2. Schmidt A., Nanney L.B., Boyd A.S., et al. Oestrogen receptor-Β expression in melanocytic lesions. Exp Dermatol 2006, 15:971-980.
3. Ohata C., Tadokoro T., Itami S. Expression of estrogen receptor beta in normal skin, melanocytic nevi and malignant melanomas. J Dermatol 2008, 35:215-221.
4. Beral V., Ramcharan S., Faris R. Malignant melanoma and oral contraceptive use among women in California. Br J Cancer 1977, 36:804-809.
5. Ramcharan S., Pellegrin F.A., Ray R., et al. The Walnut Creek Contraceptive Drug Study 1981, Vol III. Center for Population Research, National Institute of Health, Bethesda, MD.
6. Feskanich D., Hunter D.J., Willett W.C., et al. Oral contraceptive use and risk of melanoma in premenopausal women. Br J Cancer 1999, 81:918-923.
7. Koomen E.R., Joosse A., Herings R.M., Casparie M.K., Guchelaar H.J., Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma: a population-based case-control study. Ann Oncol 2009, 20:358-564.
8. Adam S.A., Sheaves S.A., Wright N.H., et al. A case-control study of the possible association between oral contraceptives and malignant melanoma. Br J Cancer 1981, 44:45-50.
9. Bain C., Hennekens C.h., Speizer F.E., et al. Oral contraceptive use and malignant melanoma. J Natl Cancer Inst 1982, 68:537-539.
10. Holly E.A., Weiss N.S., Liff J.M. Cutaneous melanoma in relation to exogenous hormones and reproductive factors. J Natl Cancer Inst 1983, 70:827-831.
11. Beral V., Evans S., Shaw H., et al. Oral contraceptive use and malignant melanoma in Australia. Br J Cancer 1984, 50:681-685.
12. Holman C.D.J., Armstrong B.K., Heenan P.J. Cutaneous malignant melanoma in women: exogenous sex hormones and reproductive factors. Br J Cancer 1984, 50:673-680.
13. Helmrich S.P., Rosenberg L., Kaufman D.W., et al. Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. J Natl Cancer Inst 1984, 72:617-620.
14. Gallagher R.P., Elwood J.M., Hill G.B., et al. Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br J Cancer 1985, 52:901-907.
15. Green A., Bain C. Hormonal factors and melanoma in women. Med J Aust 1985, 142:446-448.
16. Osterlind A., Tucker M.A., Stone B.J., et al. The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int J Cancer 1988, 42:821-824.
17. Zanetti R., Franceschi S., Rosso S., et al. Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int J Epidemiol 1990, 19:522-526.
18. Hannaford P.C., Villard-Mackintosh L., Vessey M.P., et al. Oral contraceptives and malignant melanoma. Br J Cancer 1991, 63:430-433.
19. Lê M.G., Cabanes P.A., Desvignes V., et al. Oral contraceptive use and risk of cutaneous malignant melanoma in a case-control study of French women. Cancer Causes Control 1992, 3:199-205.
20. Palmer J.R., Rosenberg L., Strom B.L., et al. Oral contraceptive use and risk of cutaneous malignant melanoma. Cancer Causes Control 1992, 3:547-554.
21. Holly E.A., Cress R.D., Ahn D.K. Cutaneous melanoma in women. III. Reproductive factors and oral contraceptive use. Am J Epidemiol 1995, 141:943-950.
22. Westerdahl J., Olsson H., Masback A., et al. Risk of malignant melanoma in relation to drug intake, alcohol, smoking and hormonal factors. Br J Cancer 1996, 73:1126-1131.
23. Smith M.A., Fine J.A., Barnhill R.L., et al. Hormonal and reproductive influences and risk of melanoma in women. Int J Epidemiol 1998 Oct, 27:751-757.
24. Lea C.S., Holly E.A., Hartge P., et al. Reproductive risk factors for cutaneous melanoma in women: a case-control study. Am J Epidemiol 2007, 165:505-513.
25. Naldi L., Altieri A., Imberti G.L., et al. Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. Ann Epidmiol 2005, 15:545-550.
26. Gefeller O., Hassan K., Wille L. Cutaneous malignant melanoma in women and the role of oral contraceptives. Br J Dermatol 1998, 38:122-124.
27. Pfahlberg A., Hassan K., Wille L., et al. Systematic review of case-control studies: oral contraceptives show no effect on melanoma risk. Public Health Rev 1997, 25:309-315.
28. Karagas M.R., Stuckel T.A., Dykes J., et al. A pooled analysis of 10 case-control studies of melanoma and oral contraceptive use. Br J Cancer 2002, 86:1085-1092.
29. Persson I., Yuen J., Bergkvist L., et al. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long term follow up of a Swedish cohort. Int J Cancer 1996, 67:327-332.
30. Holly E.A., Cress R.D., Ahn D.K. Cutaneous melanoma in women: ovulatory life, menopause, and use of exogenous estrogens. Cancer Epidemiol Biomarkers Prev 1994, 3:661-668.
31. MacKie R.M., Bray C.A. Hormone replacement therapy after surgery for stage 1 or 2 cutaneous melanoma. Br J Cancer 2004, 90:770-772.
32. Lambe M., Thorn M., Sparen P., et al. Malignant melanoma: reduced risk associated with early childbearing and multiparity. Melanoma Res 1996, 6:147-153.
33. Kaae J., Andersen A., Boyd H.A., et al. Reproductive history and cutaneous malignant melanoma: a comparison between women and men. Am J Epidemiol 2007, 165:1265-1270.
34. Freedman D.M., Sigurdson A., Doody M.M., et al. Risk of melanoma in relation to smoking, alcohol intake, and other factors in a large occupational cohort. Cancer Causes Control 2003, 14:847-857.
35. Karagas M.R., Zens M.S., Stukel T.A., et al. Pregnancy history and incidence of melanoma in women: a pooled analysis. Cancer Causes Control 2006, 17:11-19.
36. Pack G.T., Scharnagel I.M. The prognosis for malignant melanoma in the pregnant women. Cancer 1951, 4:324-334.
37. Byrd B.F., McGanity W.J. The effect of pregnancy on the clinical course of malignant melanoma. South Med J 1954, 47:196-200.
38. Conybeare R.C. Malignant melanoma in pregnancy: report of three cases. Obstet Gynecol 1964, 24:451-454.
39. Pennington D.G. Multiple primary melanoma in pregnancy: a case report. Br J Plastic Surg 1983, 36:260-261.
40. Riberti C., Marola G., Bertani A. Malignant melanoma: the adverse effect of pregnancy. Br J Plastic Surg 1981, 34:338-339.
41. Driscoll M.S., Grant-Kels J.M. Hormones, nevi and melanoma: an approach to the patient. J Am Acad Dermatol 2007, 57:919-931.
42. Reintgen D.S., McCarty K.S., Vollmer R., et al. Malignant melanoma and pregnancy. Cancer 1985, 55:1340-1344.
43. McManamny D.S., Moss A.L.H., Pocock P.V., et al. Melanoma and pregnancy: a long-term follow-up. Br J Obstet Gynecol 1989, 96:1419-1423.
44. Wong J.H., Sterns E.E., Kopald K.H., et al. Prognostic significance of pregnancy in stage I melanoma. Arch Surg 1989, 124:1227-1231.
45. Slinguff C.L., Reintgen D.S., Vollmer R., et al. Malignant melanoma arising during pregnancy: a study of 100 patients. Ann Surg 1990, 211:552-559.
46. Daryanani D., Plukker J.T., De Hullu J.A., et al. Pregnancy and early-stage melanoma. Cancer 2003, 97:2248-2253.
47. MacKie R.M., Bufalino R., Morabito A., et al. Lack of effect of pregnancy on outcome of melanoma. Lancet 1991, 337:653-655.
48. Lens M.B., Rosdahl I., Albom A., et al. Effect of pregnancy on survival in women with cutaneous malignant melanoma. J Clin Oncol 2004, 22:4369-4375.
49. O'Meara A.T., Cress R., Xing G., et al. Malignant melanoma in pregnancy: a population-based evaluation. Cancer 2005, 103:1217-1226.
50. Shaw J.H.F. Malignant melanoma in Auckland, New Zealand. Surg Gynecol Obstet 1988, 166:425-430.
51. Hersey P., Morgan G., Stone D.E., et al. Previous pregnancy as a protective factor against death from melanoma. Lancet 1977, 1:451-452.
52. Elwood J.M., Coldman A.J. Previous pregnancy and melanoma prognosis. Lancet 1978, 2:1000-1001. [letter].
53. Rampen F.H.J., Mulder J.H. Malignant melanoma: an androgen-dependent tumour?. Lancet 1980, 1:562-565.
54. Lederman J.S., Sober A.J. Effect of prior pregnancy on melanoma survival [letter]. Arch Dermatol 1985, 121:716.
55. Coulbourn D.S., Nathanson L., Belilos E. Pregnancy and malignant melanoma. Semin Oncol 1989, 16:377-387.
56. Bork K., Brauninger W. Prior pregnancy and melanoma survival [letter]. Arch Dermatol 1986, 122:1097.
57. Bork K., Brauninger W. Endocrine influences on malignant melanoma. Dtsch Med Wochenschr 1981, 106:1329-1333.
58. Schwartz J.L., Mozurkewich E.L., Johnson T.M. Current management of patients with melanoma who are pregnant, want to get pregnant, or do not want to get pregnant. Cancer 2003, 97:2130-2133.